Q2 FY2026 EarningsQ2 FY2026 miss across key profitability metrics: EPS (GAAP) was -$0.20 vs. -$0.1875 expected, and Net Loss (GAAP) reached $8.6M vs. $6.6M expected. Revenue remains at $0 as the lead product candidate OST-HER2 continues Phase IIb trials. Operating loss widened to $8.6M, significantly missing the consensus of $7.3M, primarily driven by a surge in research and development expenses related to regulatory preparation.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: OS Therapies(OSTX) the EBIT is -8.576 M (-77.23%), Miss estimate;the EPS is -0.2 (-5.26%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.01B77.23%
-0.01B51.03%
-0.00B26.20%
EPSMiss expectations
-0.25.26%
-0.18751.32%
-0.01256.58%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf